Waters has integrated new artificial intelligence and machine learning capabilities into its Empower platform, which already serves half a million users in drug development. The AI module promises to cut manual interventions by 95%, boost testing accuracy by 76%, and halve the time required for routine assays. By automating data capture and analysis, the tool aims to accelerate the pipeline from discovery to market for a range of therapeutics, from aspirin to newer obesity treatments like Wegovy.

Industry analysts see this as a pivotal step toward fully digitalized pharmaceutical R&D, where AI can reduce costly bottlenecks and improve reproducibility. If the claimed efficiency gains hold, pharmaceutical firms could see faster time‑to‑launch for new drugs and lower development costs, potentially reshaping competitive dynamics in a sector traditionally slow to adopt advanced analytics.

This story was written by a language model from reporting by Fortune. Check the original before quoting it.